Leica Biosystems is a global leader in workflow solutions and automation. As the only company to own the workflow from biopsy to diagnosis, we are uniquely positioned to break down the barriers between each of these steps. Our mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of our corporate culture. Our easy-to-use and consistently reliable offerings help improve workflow efficiency and diagnostic confidence. The company is represented in over 100 countries. It has manufacturing facilities in 9 countries, sales and service organizations in 19 countries, and an international network of dealers. The company is headquartered in Nussloch, Germany. Visit LeicaBiosystems.com for more information.
Location: Germany, Baden-Württemberg, Nußloch
Employees: 1001-5000
Founded date: 1989
Mentions in press and media 10
| Date | Title | Description |
| 30.09.2024 | Vienna-based Flinn.ai secures €10 million to automate quality and regulatory medtech compliance | Flinn.ai, a leading provider of software solutions for the automation and optimisation of compliance processes for medtech companies, has raised €10 million in investment in just 18 months. Cherry Ventures led the current financing round. W... |
| 22.08.2024 | Accelerating Translational Research with High-Performance Automated InSituPlex® Assays, Upcoming Webinar Hosted by Xtalks | www.ultivue.com In this free webinar, learn how the InSituPlex biomarker detection assays facilitate high-confidence biomarker analysis with enhanced sensitivity and specificity. Attendees will discover the simplicity of the workflow while ... |
| 14.08.2024 | NeuroTherapia Secures $12.3 Million to Combat Neuroinflammation in Alzheimer’s Disease | In the ever-evolving landscape of biotechnology, NeuroTherapia stands out as a beacon of hope. This clinical-stage company, nestled within the Cleveland Clinic Innovations portfolio, has recently secured $12.3 million in Series B funding. T... |
| 09.08.2024 | Biotechnology Research Roles at Danaher Corporation | Share Tweet Share Share Email Biotechnology is a fast growing field that merges the boundaries of biology and technology to create innovative solutions for some of the world’s most pressing challenges. From developing new pharmaceuticals to... |
| 06.03.2024 | Cryostat Market is Anticipated to Exhibit a Valuation of US$4.4 Bn in 2030, Thriving at A CAGR of 5.2% Between 2023 to 2030. | - |
| 10.08.2023 | Digital Pathology Insights — A Practical Guide to Creating Digital Ready Slides, Upcoming Webinar Hosted by Xtalks | Xtalks Life Science Webinars Standardization of histological slide preparation requires focusing on optimizing individual workflow steps and a holistic overview of the complete process from sample acquisition right through to diagnosis. Tor... |
| 03.10.2022 | Leica, Philips come out on top in digital pathology systems market, KLAS finds | Digital pathology has become increasingly common among European healthcare providers, and the technology is now gaining traction in the U.S. Because this market is poised for expeditious growth, leading technology vendors are competing for ... |
| 12.07.2016 | A ‘scientific deli slicer’ that offers pathologists a high-tech look at tumors | As diagnostics turn molecular, the standard pathologist techniques of tissue staining and mounting are looking antiquated. Bay Area upstart 3Scan hopes to change that. 3Scan is developing a computerized biopsy tool. It works by shaving tiss... |
| 03.02.2015 | Big data in pathology: 3Scan’s 3D tissue imaging platform offers reams of data on scale of gene sequencing | The company allows researchers – pathologists in particular – to get an extreme close-up of the 3-D structure of tissues and organ structures. 3Scan’s Knife Edge Scanning Microscope automatically sections and images tissue samples, spitting... |
| - | Big data in pathology: 3Scan’s 3D tissue imaging platform offers reams of data on scale of gene sequencing | This one’s a big data play for the pathologist set: Bay Area startup 3Scan is developing an ultra high-res, 3-D tissue imaging platform that’s churning out data on the scale of whole-genome sequencing. The startup just raised $6.7 million i... |